PROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 52-Week Low Following Weak Earnings

Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) hit a new 52-week low during trading on Thursday following a dissappointing earnings announcement. The stock traded as low as $19.35 and last traded at $20.9420, with a volume of 1508954 shares trading hands. The stock had previously closed at $27.84.

The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The firm had revenue of $76.38 million for the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative return on equity of 24.82% and a negative net margin of 31.02%.PROCEPT BioRobotics’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.35) EPS.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Solid cash runway and improving operating losses — Q4 showed an improved operating loss and the company ended the quarter with roughly $286.5M in cash and total liabilities of $142.2M, which supports near‑term execution. Quiver Quant Earnings Summary
• Positive Sentiment: FY‑2026 revenue guidance range ($390M–$410M) was raised/updated and sits near analyst consensus, giving some multi‑quarter visibility for modeling. Q4 Results & Guidance (GlobeNewswire)
• Neutral Sentiment: Company hosted an Investor Day outlining its multi‑year plan — strategic detail may help longer‑term sentiment but did not offset near‑term headline risk. Investor Day Release
• Negative Sentiment: Earnings and revenue misses — Q4 revenue of ~$76.4M (+11.9% YoY) and diluted loss of $0.53 missed consensus (revenue and EPS), and Q1 revenue guidance ($79M–$82M) came in well below street expectations — the primary catalyst for selling. Q4 Results & Guidance (GlobeNewswire)
• Negative Sentiment: New securities‑fraud investigation announced by law firm Ademi LLP, alleging possible inaccurate statements about financials/operations — this raises regulatory/legal overhang and investor risk. Ademi LLP Investigation
• Negative Sentiment: Multiple analyst price‑target cuts and a Bank of America downgrade to underperform (PT $20) plus cuts from Leerink, TD Cowen and Piper Sandler increased selling pressure; some firms remain constructive but consensus risk has risen. Analyst Coverage/Benzinga TD Cowen Comment
• Negative Sentiment: Heavy institutional selling and a spike in volume pushed the stock to a 52‑week low; hedge‑fund and mutual‑fund position reductions magnified the decline. Quiver Quant (institutional moves) Benzinga: 52‑Week Low

Analyst Ratings Changes

Several brokerages have recently issued reports on PRCT. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Thursday, January 22nd. Piper Sandler cut their target price on shares of PROCEPT BioRobotics from $50.00 to $28.00 and set an “overweight” rating for the company in a research note on Thursday. UBS Group initiated coverage on shares of PROCEPT BioRobotics in a research report on Friday, December 12th. They issued a “buy” rating and a $62.00 price target on the stock. Bank of America downgraded PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and cut their price objective for the company from $38.00 to $20.00 in a research report on Thursday. Finally, Jefferies Financial Group raised PROCEPT BioRobotics from a “hold” rating to a “strong-buy” rating in a research note on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PRCT. Advisory Services Network LLC lifted its stake in PROCEPT BioRobotics by 1.3% in the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock worth $1,158,000 after acquiring an additional 250 shares in the last quarter. Vega Investment Solutions increased its holdings in shares of PROCEPT BioRobotics by 52.0% in the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock valued at $45,000 after purchasing an additional 265 shares during the period. Frank Rimerman Advisors LLC lifted its position in shares of PROCEPT BioRobotics by 0.3% in the third quarter. Frank Rimerman Advisors LLC now owns 122,389 shares of the company’s stock worth $4,368,000 after purchasing an additional 307 shares in the last quarter. RiverPark Advisors LLC boosted its holdings in shares of PROCEPT BioRobotics by 22.5% during the second quarter. RiverPark Advisors LLC now owns 1,761 shares of the company’s stock worth $101,000 after purchasing an additional 324 shares during the period. Finally, Osaic Holdings Inc. boosted its holdings in shares of PROCEPT BioRobotics by 20.3% during the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock worth $115,000 after purchasing an additional 337 shares during the period. Hedge funds and other institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Price Performance

The stock has a market capitalization of $1.32 billion, a PE ratio of -13.82 and a beta of 0.99. The company has a quick ratio of 7.20, a current ratio of 8.44 and a debt-to-equity ratio of 0.14. The stock’s 50-day moving average is $30.18 and its 200 day moving average is $33.64.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.